Thrombocytopenia remains a serious problem in patients treated with intensive high-dose chemotherapy and haematopoietic stem cell transplantation. This condition is especially apparent after umbilical cord blood transplant when the platelet recovery time is frequently delayed compared with transplants using bone marrow or mobilised peripheral blood stem cells. 1, 2 The infusion of ex vivo expanded megakaryocytic (MK) progenitors to transplant patients has been proposed as a strategy for accelerating platelet recovery. Several clinical trials using expanded peripheral blood stem cells 3, 4 and bone marrow 5 have demonstrated some success in alleviating thrombocytopenia after high-dose chemotherapy.
A number of cytokines are known to regulate megakaryocytopoiesis in vivo and enhance the expansion of MK cells in vitro. TPO has been identified as the most effective cytokine for megakaryocytopoiesis as it acts on different developmental stages. 6, 7 IL-1 enhances the proliferation of MK progenitors. 8, 9 IL-3 increases the absolute number of CD34 + CD41 + cells in liquid culture 6, 7 and expands the number of MK colonies. 10 ,11 IL-6 or IL-11 enhance effects of other growth factors, such as IL-3 and IL-1, on the induction of MK differentiation, and they stimulate late stages of MK development. 12, 13 Flt-3L and SCF promote the growth of MK colonies, possibly via their direct stimulation of CD34 + cells. 14, 15 Platelet-derived growth factor (PDGF) is a member of the connective tissue growth factor family which includes vascular endothelial growth factor, basic fibroblast growth factor and tumor necrosis factor-␤. Initially it was isolated from human platelets as a protein with a molecular mass of 28-31 kDa. 16, 17 PDGF consists of two polypeptide chains, designated A and B, linked together by disulphide bonds. 18 PDGF exists in three isoforms (AA, AB and BB). PDGF-BB binds to both PDGF ␣-and ␤-receptors and possesses stronger mitogenic activity than the other two isoforms. 19 PDGF does not only stimulate the growth and differentiation of connective tissue cells, such as fibroblasts, endothelial cells and smooth muscle cells, 20 but also affects haematopoiesis. PDGF-B and ␤-receptor knock-out mice develop haemorrhage and edema, 21, 22 but the mechanism remains unclear. PDGF also promotes in vitro multipotent haematopoietic progenitors and erythropoiesis. 23, 24 In previous studies, we demonstrated the presence of functional PDGF receptors on human MK and MK cell lines 25 and
showed that PDGF promoted MK colony formation. 26 In this study, we aimed to establish a cytokine combination for the efficient ex vivo expansion of the MK lineage from umbilical cord blood CD34 + cells, and to investigate the effect of PDGF in this system. Our read-out criteria included CD34
+ stem and progenitor cells, colony-forming progenitor cells of the MK lineage (CFU-MK), CD61
+ CD41 + cells and their ploidy/maturation status.
Materials and methods

Human cord blood collection
Umbilical cord blood samples were collected into preservative free heparin (100 IU/ml, David Bull Laboratories, Victoria, Australia) following normal, full-term vaginal delivery. These samples were kept at room temperature and processed within 24 h. /ml were cultured in Iscove's modified Dulbecco's medium (IMDM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS; Gibco) in a 24-well plate (Costar, Cambridge, MA, USA) at 37°C in a fully humidified atmosphere containing 5% CO 2 . Cultures contained the indicated combinations of growth factors. On days 7 and 10, 2 and . volume of the media were changed, respectively. On days 7 and 14, CFU-MK and cell surface expression of CD41 and CD61 antigens were analysed. On day 14, the ploidy status of MK cells was measured by flow cytometry. Viable cell counts were determined by trypan blue exclusion and nucleated cell were counted using a haemocytometer.
Cytokines used in the experiments were: recombinanthuman PDGF-BB (50 ng/ml), TPO (50 ng/ml), IL-1␤ (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), Flt-3L (20 ng/ml). All cytokines, unless otherwise specified, were products of Pepro Tech (Rocky Hill, NJ, USA). The optimal concentrations of these cytokines were determined in previous studies. 9, 14, [25] [26] [27] Flow cytometry analysis of cell surface markers and ploidy
Enriched CD34
+ cells or cultured cells were incubated with fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-labeled monoclonal antibodies or their respective isotypic controls, for 30 min at room temperature. These cells were washed with PBS/0.2% BSA and analysed by the FACScan instrument (Becton Dickinson (BD), San Jose, CA, USA). Ten thousand and 30 000 events were acquired for each sample before and after expansion, respectively, with dead cells and debris being gated out by the forward and side scatter profiles during data analysis. The following monoclonal antibodies were used: IgG1-FITC (BD); IgG1-PE (BD); CD61-FITC (Dako, Copenhagen, Denmark); CD41-PE (Dako); CD34-FITC (BD).
MK ploidy was measured by a two-colour, flow cytometric technique described by Debili et al 7 with slight modifications. On day 14, cells were harvested and washed with PBS/0.2% BSA. They were then labeled with 20 l of CD61-FITC/1 × 10 6 cells at room temperature in the dark for 30 min. After washing, these cells were resuspended in 0.3 ml Saponin (0.1%, Sigma, Saint Louis, MO, USA) and incubated at room temperature for 10 min before the addition of 0.1 ml of RNase (2.5 mg/ml; Bio-Rad, Hertfordshire, UK) for another 10 min. Finally, 0.2 ml of propidium iodide (250 g/ml; Sigma) was added and incubated for 10 min before analysis by flow cytometer. Seventy thousand events were acquired for ploidy analysis. The doublet discrimination function of the CellFIT software (BD) was used to gate in single cells only.
CFU-MK assay
On days 0, 7 and 14, 3000 cells /ml were seeded into 24-well plates in triplicate with 0.5 ml in each well. The culture contained IMDM supplemented with 30% FCS, 1% BSA, 1.3% methylcellulose, 50 ng/ml TPO and 20 ng/ml IL-3. After 14 days of incubation at 37°C, 5% CO 2 , CFU-MK were identified microscopically and scored as a group of more than three MK cells in a cluster. 8 
Morphological analysis
Cultured cells (day 14) were cytospun on to glass slides and stained with May-Grunwald-Giemsa. 27 Cell morphology was examined by light microscopy.
Statistical analysis
Statistical analysis was performed using the SigmaStat software (Jandel Scientific Software, San Rafael, USA). Comparisons between treatment groups were performed by the analysis of variance and the paired t-test or Wilcoxon sign rank test, where appropriate. A P value of р0.05 was considered as statistically significant. All values were expressed as mean Ϯ standard error of mean (s.e.m.).
Results
Expansion of nucleated cells and CD34
+ cells
The purity of the enriched CD34 + cells was 95.1 Ϯ 0.71% (range 93.3-98.3%; n = 7). The absolute numbers of expanded cells were significantly higher on day 14 when compared with those from day 7 in all treatment groups (P Ͻ 0.05, Table 1 ). On day 14, total cell counts were significantly lower in cultures treated with TPO or TPO + IL-1␤ when compared with those treated with three or more growth factors (P Ͻ 0.05). The significant enhancing effects of PDGF were observed in most cytokine groups on days 7 and 14 (Table 1 ). Cell viability as tested by trypan blue exclusion assay was high on day 7 (mean value over 95% for all groups). On day 14, cell viability was well maintained in groups treated with three or more cytokines (mean 86.3-92.2%) but was significantly lower in the TPO or TPO + IL-1␤ groups with or without PDGF (mean 67.2-73.5%). CD34 + cells were not expanded in the presence of TPO or TPO + IL-1␤ on day 7 (mean 0.70-1.05-fold) or day 14 (mean 0.27-1.04-fold). Additional cytokines appeared to enhance the CD34 + cell yield. Significant increases in CD34 + cells were observed in cultures with TPO + IL-6 + Flt-3L when compared with those containing one or two cytokines (P Ͻ 0.05) with or without PDGF. Flt-3L significantly increased the numbers of CD34 + cells on day 7 (P Ͻ 0.006) and day 14 (P Ͻ 0.05) when compared with the respective controls but IL-1␤ or IL-3 did not have such effects. The addition of PDGF significantly increased the yield of CD34
+ cells in most treatment groups (Table 1 ) to up to 31.4-fold on day 14.
Expansion of CD41
+ CD61 + cells
The proportions of CD41 + CD61 + cells were high with mean values over 75% in cultures expanded with TPO alone (Table 1 ). However, due to relatively low cell counts, the Table 1 Ex vivo expansion of cord blood CD34 + cells The cell populations were derived from the cultures of 4 × 10 4 CD34 + cells at day 0. Parameters in cultures with and without PDGF were compared. −P = without PDGF; +P = with PDGF; N = 7. *P Ͻ 0.05; **P Ͻ 0.01.
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+ CD61 + cells was lowest. On day 7, the addition of IL-1␤ maintained the proportion of these cells and significantly increased total cell number when the respective groups were compared (P Ͻ 0.05). Similar trends were observed on day 14 but the differences were not significant. While the addition of Flt-3L did not have such effect, IL-3 increased CD41 + CD61 + cells on day 7 (P Ͻ 0.016) but not on day 14. The addition of PDGF to these cytokine combinations enhanced the yield of total CD41 + CD61 + cells but had little effect on their proportions in the culture (Table 1) .
Expansion of megakaryocytic progenitor cells (CFU-MK)
On days 7 and 14, the trends in CFU-MK expansion were in general similar to those of CD41 + CD61 + cells as indicated in Table 1 and Figure 1 . The expansion outcomes were inferior with TPO alone or with TPO + IL-1␤ (P Ͻ 0.05). At day 7, either IL-1␤ or Flt-3L significantly increased CFU-MK when compared with respective groups without the cytokines (P Ͻ 0.05). A similar effect was observed on day 14 at which time a significant enhancement of CFU-MK by IL-1␤ was observed in the TPO groups with or without PDGF (P Ͻ 0.05). The effect of Flt-3L was demonstrated in the TPO + IL-1␤ group without PDGF (P = 0.039). Again, PDGF significantly enhanced the expansion of CFU-MK in most cytokine combination groups (Figure 1 ). In the four treatment groups with three to five cytokines, mean CFU-MK were expanded by 122-409-fold and the addition of PDGF improved the yield by 30-134%. 
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Polyploidisation of megakaryocytes
At day 14, polyploid cells (4N, 8N, 16N, 32N) were present in the CD61 + population but not among CD61 − cells (Figure 2 ). The majority of CD61 + cells were 2N (mean 82.5-87.1%) and 4N (11.2-14.8%), with a consistent but low proportion of 8N (1.38-2.39%), 16N (0.16-0.27%) and 32 N (0-0.01%) cells. The distribution of ploidy was not 
Figure 3
Effect of cytokines and PDGF on megakaryocyte ploidy distribution. The ploidy status of CD61 + cells was analysed by two-colour flow cytometry using CD61-FITC/propidium iodide staining after 14 days of culture with T = TPO; 1 = IL-1␤; 3 = IL-3; 6 = IL-6; F = Flt-3L; P = PDGF. Treatment 1 = T alone; 2 = T+P; 3 = T+1; 4 = T+1+P; 5 = T+1+F; 6 = T+1+F+P; 7 = T+6+F; 8 = T+6+F+P; 9 = T+3+6+F; 10 = T+3+6+F+P; 11 = T+1+3+6+F; 12 = T+1+3+6+F+P. Seven independent experiments were performed and no significant differences were observed between treatment groups with or without PDGF.
affected by cytokine treatments or the presence of PDGF (Figure 3 ). Morphological features of these cells and the presence of polyploid nuclei were confirmed under microscopy ( Figure 4 ).
Discussion
Bertolini et al 3 demonstrated the safe administration of ex vivo expanded megakaryocytic progenitors from autologous peripheral blood progenitor cells to 10 cancer patients and observed that platelet transfusion support was not required in two of the four patients receiving the highest doses of expanded cells. Paquette et al 4 reported that the infusion of 30 in spite of the reduction in post-transplant neutropenia. An efficient system for the ex vivo expansion and a resultant high cell dose of megakaryocytic progenitor cells could be critical factors for producing the desired clinical outcomes.
In this study, we assessed the efficiency of early-acting cytokines Flt-3L, IL-1␤, IL-6 and IL-3 in combination with TPO on the expansion and maturation of CD34-enriched cells into the MK lineage. In addition, we investigated the effects of PDGF on the expansion systems. Our data demonstrated that culture for 14 days produced moderate expansions of CD34 + cells and high increases of MK progenitors (CFU-MK) and CD61
+ CD41 + cells. The presence of TPO alone resulted in a high proportion of CD61 + CD41 + cells to over 70% but low total cell counts and high cell death, leading to an inferior expansion overall. The addition of IL-1␤ maintained the proportion of these cells in the culture and significantly increased total cell number. This observation supported the proposal that IL-1␤ might play an important role in the MK lineage 9 and expansion. 8, 31 The number of dead cells was low in cultures with three or more cytokines in spite of the high cell density, possibly contributed by the anti-apoptotic effect of Flt-3L. 32 Consistent with our previous report, 14 Flt-3L significantly increased CFU-MK. IL-3 increased CFU-MK and CD61 + CD41 + cells on day 7 but not on day 14. In general, the treatment groups with three to five cytokines produced efficient expansions of CFU-MK up to 400-fold with the highest yield being observed in the presence of TPO, IL-1␤, IL-3, IL-6 and Flt-3L. With these cytokine combinations, CD34
+ cells were moderately expanded by five-to 22-fold.
PDGF improved the expansion of all cell types. The maximal increases of CD61 + CD41 + cells, CFU-MK and CD34
+ cells on day 14 were 101%, 134% and 70%, respectively, when compared to those in cultures without PDGF. The marked expansion of CFU-MK and CD41
+ CD61 + cells suggested that a highly proliferative compartment of MK was responding to the various cytokine combinations. We evaluated the DNA content of CD61 + cells on day 14 and demonstrated that a small number of polyploid cells was observed among the CD61 + cells. Their proportions were not affected by PDGF or other cytokines. This observation was in agreement with that of Dolzhanskiy et al, 10 who demonstrated that TPO alone significantly increased MK cell ploidy but neither SCF nor IL-3 enhanced this effect. The mechanism of PDGF on the expansion to MK lineage is unclear. Since PDGF ␣-and ␤-receptors are expressed on human bone marrow MK and several human MK cell lines and platelets, 25 PDGF might exert a direct stimulating effect on this lineage. However, we cannot rule out the possibility of additional indirect effect of PDGF such as activation of the secretion of growth promoting factors by other haematopoietic cells or stromal cells in the culture. 33, 34 Our data revealed that polyploid nuclear formation
Bone Marrow Transplantation was observed after 14 days of culture, indicating a normal developmental process for the MK lineage. PDGF might act on the early stage of differentiation and proliferation without stimulating polyploidisation and terminal maturation.
In conclusion, we have reported for the first time that the simultaneous use of multiple MK-promoting cytokines and PDGF resulted in a marked ex vivo expansion of the MK lineage from cord blood CD34 + cells. This represented a highly efficient system for expanding the MK lineage while CD34
+ cells were also effectively expanded. PDGF did not appear to affect the in vitro maturation process, with respect to polyploid nucleus formation. PDGF might be a suitable growth factor to enhance the ex vivo expansion of MK progenitors for clinical applications.
